13F Pro13F Pro

Bellevue Group AG

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1674546
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.2%$4.7B
  • Technology0.4%$19.0M
  • Consumer Staples0.2%$7.6M
  • Industrials0.1%$6.6M
  • Other0.1%$2.5M
  • Consumer Discretionary0.0%$382,536

AUM History

13fpro.ai/research/fund/bellevue-group-ag-1674546

Conviction and streaks

Stable · top 10 = 42.9%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

AMGN$AMGNConviction hold6.5% weight · held 10 quartersVRTX$VRTXConviction hold6.0% weight · held 10 quartersARGX$ARGXConviction hold5.9% weight · held 10 quartersGILD$GILDConviction hold5.7% weight · held 10 quartersRVMD$RVMDConviction hold4.1% weight · held 10 quartersBBIO$BBIOAccumulating+11338% shares · 4 quarters runningMDGL$MDGLAccumulating+325% shares · 4 quarters runningAMGN$AMGNAccumulating+5582% shares · 3 quarters runningGILD$GILDAccumulating+4227% shares · 3 quarters runningVRDN$VRDNAccumulating+35146% shares · 3 quarters runningARGX$ARGXTrimming-63% shares · 9 quarters runningISRG$ISRGTrimming-63% shares · 9 quarters runningBSX$BSXTrimming-72% shares · 9 quarters runningAXSM$AXSMTrimming-100% shares · 9 quarters runningPODD$PODDTrimming-71% shares · 8 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/bellevue-group-ag-1674546

Bellevue Group AG 13F holdings — Q2 2026

$4.8B portfolio (+13.1% QoQ) · 148 holdings · Q2 2026 13F · top 10 are 43% of the stock portfolio

All holdings — Bellevue Group AG (Q2 2026)

148 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
RLAY$RLAYRelay Therapeutics, Inc.$115.7M-21%
PCVX$PCVXVaxcyte, Inc.$114.6M+66%
UTHR$UTHRUNITED THERAPEUTICS Corp$102.1M+8976%
ISRG$ISRGINTUITIVE SURGICAL INC$101.3M-11%
REGN$REGNREGENERON PHARMACEUTICALS, INC.$98.1M-44%
CRNX$CRNXCrinetics Pharmaceuticals, Inc.$98.0M-20%
BBIO$BBIOBridgeBio Pharma, Inc.$88.6M+4587%
IMCR$IMCRImmunocore Holdings plcadr$88.5M-0.3%
ABT$ABTABBOTT LABORATORIES$85.9M-18%
SYK$SYKSTRYKER CORP$84.5M+24%
MDT$MDTMedtronic plc$77.8M+4%
IONS$IONSIONIS PHARMACEUTICALS INC$77.1M-47%
ELVN$ELVNEnliven Therapeutics, Inc.$75.6M-36%
VERA$VERAVera Therapeutics, Inc.$73.4M+0.0%
JBIO$JBIOJade Biosciences, Inc.$67.9M-13%

What changed in Q2 2026

Against the previous quarter's 13F: 17 new, 41 added to, 66 trimmed, 24 sold out. Share-count changes; largest moves by dollar size first.

New positions (17)

  • AVLN$AVLNAvalyn Pharma Inc.$44.4M

    first bought this quarter

  • CGON$CGONCG Oncology, Inc.$35.1M

    first bought this quarter

  • SPTX$SPTXSeaport Therapeutics, Inc.$23.9M

    first bought this quarter

  • PVLA$PVLAPALVELLA THERAPEUTICS, INC.$23.7M

    first bought this quarter

  • SYRE$SYRESpyre Therapeutics, Inc.$20.4M

    first bought this quarter

  • COAG$COAGHemab Therapeutics Holdings, Inc.$20.2M

    first bought this quarter

+11 more in the Excel export

Added to (41)

  • AMGN$AMGNAMGEN INC+188%

    now $308.4M · held 10+ qtrs, 3 adds in a row

  • GILD$GILDGILEAD SCIENCES, INC.+85%

    now $272.7M · held 10+ qtrs, 3 adds in a row

  • ORKA$ORKAOruka Therapeutics, Inc.+227%

    now $157.7M · held 2 qtrs, 2 adds in a row

  • UTHR$UTHRUNITED THERAPEUTICS Corp+8976%

    now $102.1M · held 4 qtrs

  • BBIO$BBIOBridgeBio Pharma, Inc.+4587%

    now $88.6M · held 10+ qtrs, 4 adds in a row

  • PCVX$PCVXVaxcyte, Inc.+66%

    now $114.6M · held 2 qtrs, 2 adds in a row

+35 more in the Excel export

Trimmed (66)

  • KRYS$KRYSKrystal Biotech, Inc.-84%

    now $28.8M · held 10+ qtrs

  • RVMD$RVMDRevolution Medicines, Inc.-32%

    now $196.3M · held 10+ qtrs, 3 trims in a row

  • REGN$REGNREGENERON PHARMACEUTICALS, INC.-44%

    now $98.1M · held 10+ qtrs

  • ALNY$ALNYALNYLAM PHARMACEUTICALS, INC.-100%

    now $329K · held 10+ qtrs, 2 trims in a row

  • IONS$IONSIONIS PHARMACEUTICALS INC-47%

    now $77.1M · held 10+ qtrs, 4 trims in a row

  • SRRK$SRRKScholar Rock Holding Corp-32%

    now $134.7M · held 10+ qtrs, 2 trims in a row

+60 more in the Excel export

Sold out (24)

  • EWTX$EWTXEdgewise Therapeutics, Inc.was $48.1M

    held 8 qtrs

  • INSP$INSPInspire Medical Systems, Inc.was $5.1M

    held 9+ qtrs

  • PEN$PENPenumbra Incwas $4.0M

    held 9+ qtrs

  • RNA.R1599901$RNA.R1599901Avidity Biosciences, Inc.was $3.5M

    held 1 qtr

  • MASI$MASIMASIMO CORPwas $1.6M

    held 6 qtrs

  • EQNR$EQNREQUINOR ASAwas $742K

+18 more in the Excel export

Share

Holdings by quarter

Every 13F Bellevue Group AG has filed, 41 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Bellevue Group AG?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 27, 2026.

Average quality of Bellevue Group AG's top 20 holdings: 59/100 (our AI quality score, weighted by position size; 13 of the 20 are scored)

Top 10 since filing

-0.2%

Value-weighted move of the 10 largest stock positions

Turnover

24%

Last quarter; 72% over the last 4

Top 10 weight

43%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

73%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Bellevue Group AG disclosed 148 positions worth $4.8B in its Form 13F-HR for Q2 2026, led by $AMGN (AMGEN INC) at 6.5% of the equity portfolio, followed by $VRTX and $ARGX. During the quarter the fund opened 17 new positions and exited 24 — including a new stake in $AVLN and a full exit from $EWTX. The portfolio is most concentrated in Healthcare (99.2% of disclosed assets). All figures are sourced directly from Bellevue Group AG’s Form 13F-HR filing with the SEC under CIK 1674546.

Funds like this

managers whose biggest positions overlap Bellevue Group AG's
Paradigm Biocapital Advisors LP$5.34B 13F book · 7 shared top holdingsRVMDORKANUVLINSMAvoro Capital Advisors LLC$11.14B 13F book · 7 shared top holdingsARGXRVMDUTHRVERARTW INVESTMENTS, LP$11.71B 13F book · 6 shared top holdingsARGXINSMORKARARERock Springs Capital Management LP$2.05B 13F book · 12 shared top holdingsRVMDARGXSRRKINSMIntegral Health Asset Management, LLC$2.53B 13F book · 11 shared top holdingsRVMDINSMSRRKVERADeep Track Capital, LP$6.87B 13F book · 8 shared top holdingsNUVLORKAPCVXIONS

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Bellevue Group AG

13F Pro is an AI hedge fund tracker and stock research platform. For Bellevue Group AG (SEC CIK: 1674546), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Bellevue Group AG's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.